Pulmonx (LUNG) Preferred Stock Liabilities (2019 - 2020)
Pulmonx's (LUNG) quarterly Preferred Stock Liabilities came in at $207.6 million in Q3 2020, up 1.1% year-over-year from $205.3 million in Q4 2019, and little changed quarter-over-quarter from $207.6 million in Q2 2020.
Powered by 
Analysis
Pulmonx (LUNG) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Pulmonx (LUNG) has reported Preferred Stock Liabilities for 2 consecutive years, with $207.6 million the latest figure, recorded in Q3 2020.
- On a quarterly basis, Preferred Stock Liabilities rose 1.1% year-over-year to $207.6 million in Q3 2020; TTM through Sep 2020 was $207.6 million, a 1.1% increase from a year earlier, with the FY2019 full-year figure at $205.3 million, up 46.11% from the prior year.
- Preferred Stock Liabilities was $207.6 million for Q3 2020 at Pulmonx, roughly flat from $207.6 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $207.6 million in Q1 2020 and troughed at $205.3 million in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | - |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | - |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | - |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | - |
| 10 | Pulmonx | 75.94 Mn | 6.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | 207.60 Mn |
| Jun 30, 2020 | 207.60 Mn |
| Mar 31, 2020 | 207.60 Mn |
| Dec 31, 2019 | 205.34 Mn |
| Sep 30, 2019 | 205.34 Mn |